Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Myasthenia gravis.

Silvestri NJ, Wolfe GI.

Semin Neurol. 2012 Jul;32(3):215-26. doi: 10.1055/s-0032-1329200. Epub 2012 Nov 1. Review.

PMID:
23117946
2.

Treatment of myasthenia gravis.

Kumar V, Kaminski HJ.

Curr Neurol Neurosci Rep. 2011 Feb;11(1):89-96. doi: 10.1007/s11910-010-0151-1. Review.

PMID:
20927659
3.

Therapeutic options in autoimmune myasthenia gravis.

García-Carrasco M, Escárcega RO, Fuentes-Alexandro S, Riebeling C, Cervera R.

Autoimmun Rev. 2007 Jun;6(6):373-8. Epub 2007 Jan 30. Review.

PMID:
17537383
4.

Management of myasthenia gravis.

Schwendimann RN, Burton E, Minagar A.

Am J Ther. 2005 May-Jun;12(3):262-8. Review.

PMID:
15891271
5.

Treatment of autoimmune myasthenia gravis.

Richman DP, Agius MA.

Neurology. 2003 Dec 23;61(12):1652-61. Review.

PMID:
14694025
6.

Therapeutic strategies for myasthenia gravis.

Keys PA, Blume RP.

DICP. 1991 Oct;25(10):1101-8. Review.

PMID:
1803801
7.

Immunosuppressive therapies in myasthenia gravis.

Sanders DB, Evoli A.

Autoimmunity. 2010 Aug;43(5-6):428-35. doi: 10.3109/08916930903518107. Review.

PMID:
20166870
8.

Myasthenia gravis: signs, symptoms, diagnosis, immunology, and current therapy.

Scheife RT, Hills JR, Munsat TL.

Pharmacotherapy. 1981 Jul-Aug;1(1):39-54.

PMID:
6927602
9.

Myasthenia gravis. Pathogenesis and current concepts in management.

Havard CW, Scadding GK.

Drugs. 1983 Aug;26(2):174-84.

PMID:
6884241
10.

[Therapeutic strategy in myasthenia gravis].

Tranchant C.

Rev Neurol (Paris). 2009 Feb;165(2):149-54. doi: 10.1016/j.neurol.2009.01.005. Review. French.

PMID:
19233080
11.

Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.

Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, Marino M, Bartoccioni E.

Brain. 2003 Oct;126(Pt 10):2304-11. Epub 2003 Jun 23.

PMID:
12821509
12.

Management of myasthenia gravis.

Saperstein DS, Barohn RJ.

Semin Neurol. 2004 Mar;24(1):41-8. Review.

PMID:
15229791
13.

[Contribution of intravenous immunoglobulins to the treatment of myasthenia].

Gajdos P.

Ann Med Interne (Paris). 2000 May;151 Suppl 1:1S30-4. Review. French.

PMID:
10896986
14.

Diagnosis and treatment of myasthenia gravis.

Matney SE, Huff DR.

Consult Pharm. 2007 Mar;22(3):239-48. Review.

PMID:
17658970
15.

Recent approaches to the development of antigen-specific immunotherapies for myasthenia gravis.

Lagoumintzis G, Zisimopoulou P, Kordas G, Lazaridis K, Poulas K, Tzartos SJ.

Autoimmunity. 2010 Aug;43(5-6):436-45. doi: 10.3109/08916930903518099. Review.

PMID:
20187712
16.

Overview of myasthenia gravis.

Arora Y, Li Y.

Hosp Pract (1995). 2013 Oct-Nov;41(4):40-50. doi: 10.3810/hp.2013.10.1079.

PMID:
24145588
17.

[Myasthenia gravis].

Fleury MC, Tranchant C.

Rev Prat. 2008 Dec 31;58(20):2217-24. Review. French.

PMID:
19209651
18.

Response to therapy in myasthenia gravis with anti-MuSK antibodies.

Evoli A, Bianchi MR, Riso R, Minicuci GM, Batocchi AP, Servidei S, Scuderi F, Bartoccioni E.

Ann N Y Acad Sci. 2008;1132:76-83. doi: 10.1196/annals.1405.012.

PMID:
18567856
19.

Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.

Newsom-Davis J.

Semin Neurol. 2003 Jun;23(2):191-8. Review.

PMID:
12894384
20.

Pearls: myasthenia.

Benatar M.

Semin Neurol. 2010 Feb;30(1):35-7. doi: 10.1055/s-0029-1244999. Epub 2010 Feb 1.

PMID:
20127579

Supplemental Content

Support Center